Ars Technica
US · 1 hrs ago
✦ 78✓ Factual
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
78Quality
0Ratings
0Comments
AI Analysis
Quality 78/100
Partisan intensity 15/100
ObjectivePartisan
Low partisan intensity — consistent with factual reporting✓ Fair headline
A Phase I trial of a gene-editing drug showed a 62% reduction in bad cholesterol from a single dose in 35 participants, with promising interim results.
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!